Franz Berkeley, Dhanani Lindsay Y, Bogart Sean, Fenstemaker Cheyenne, Miller William C, Hall O Trent, Brook Daniel, Go Vivian
Ohio University Heritage College of Osteopathic Medicine, Institute to Advance Health Equity (ADVANCE), Athens, OH, United States of America.
Rutgers University School of Management and Labor Relations, Piscataway, NJ, United States of America.
J Subst Use Addict Treat. 2025 Apr;171:209633. doi: 10.1016/j.josat.2025.209633. Epub 2025 Jan 24.
Buprenorphine and other medications for opioid use disorder (MOUD) are highly effective but substantially under prescribed in the rural United States. Among the most cited barriers to buprenorphine prescribing is stigma, yet little progress has been made in developing successful strategies to reduce stigma and increase access to life-saving medication. One of the key challenges to developing successful implementation strategies is understanding the different types of stigma that limit implementation.
This study draws from qualitative interviews with 23 primary care professionals (PCPs) in rural Ohio. We conducted semi-structured interviews focused on prior experiences with buprenorphine, willingness to prescribe it, prior buprenorphine training, and barriers to prescribing. Thematic analysis resulted in 3 forms of stigma that must be addressed to improve implementation.
PCPs discussed 3 key forms of stigma that limit buprenorphine prescribing in rural areas: 1) stigma towards patients-PCPs feared being harmed by patients with opioid use disorder (OUD) if they began prescribing buprenorphine; 2) stigma towards providers-PCPs believed their clinics would be stigmatized if they began treating addiction; and 3) stigma towards buprenorphine-PCPs worried they might unintentionally harm patients through prescribing a partial opioid agonist.
Stigma remains a critical barrier to buprenorphine prescribing among rural PCPs but is not limited to negative attitudes towards people with OUD. Buprenorphine is also stigmatized and PCPs fear becoming stigmatized if they prescribe the medication. Implementation research is urgently needed to test whether multicomponent stigma-reduction strategies increase access to buprenorphine in rural communities.
丁丙诺啡及其他用于治疗阿片类物质使用障碍的药物(药物辅助治疗)疗效显著,但在美国农村地区的处方量却严重不足。在丁丙诺啡处方面临的诸多障碍中,耻辱感是被提及最多的因素之一,然而在制定成功的策略以减少耻辱感并增加获得救命药物的机会方面,进展甚微。制定成功实施策略的关键挑战之一是理解限制实施的不同类型的耻辱感。
本研究基于对俄亥俄州农村地区23名初级保健专业人员(PCP)的定性访谈。我们进行了半结构化访谈,重点关注他们之前使用丁丙诺啡的经历、开处方的意愿、之前接受的丁丙诺啡培训以及开处方的障碍。主题分析得出了3种耻辱感形式,如果要改善实施情况,必须加以解决。
初级保健专业人员讨论了限制农村地区丁丙诺啡处方的3种关键耻辱感形式:1)对患者的耻辱感——初级保健专业人员担心如果他们开始开具丁丙诺啡,会受到患有阿片类物质使用障碍(OUD)的患者的伤害;2)对医疗服务提供者的耻辱感——初级保健专业人员认为,如果他们开始治疗成瘾问题,他们的诊所会被污名化;3)对丁丙诺啡的耻辱感——初级保健专业人员担心通过开具部分阿片类激动剂可能会无意中伤害患者。
耻辱感仍然是农村初级保健专业人员开具丁丙诺啡的关键障碍,但不仅限于对患有阿片类物质使用障碍者的负面态度。丁丙诺啡也受到污名化,并且初级保健专业人员担心如果他们开具这种药物会被污名化。迫切需要开展实施研究,以测试多成分减少耻辱感策略是否能增加农村社区获得丁丙诺啡的机会。